跳转至内容
Merck
CN

AB9872

Anti-TrkB Antibody

serum, Chemicon®

别名:

Tyrosine kinase receptor B

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
polyclonal
Application:
IHC
Citations:
7
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


biological source

rabbit

Quality Level

conjugate

unconjugated

antibody form

serum

antibody product type

primary antibodies

clone

polyclonal

species reactivity

mouse, rat

manufacturer/tradename

Chemicon®

technique(s)

immunohistochemistry: suitable

UniProt accession no.

shipped in

dry ice

target post-translational modification

unmodified

Gene Information

human ... NTRK2(4915)

General description

The mammalian Trk family of receptor tyrosine kinases consists of three principle transmembrane proteins. The receptors can be activated by one or more of four neurotrophins - NGF, BDNF, NT3 and NT4/5. The TrkB family of transmembrane proteins serves as receptors for BDNF and NT-4/5 and these neurotrophins regulate biological responses such as cell survivial, proliferation and differentiation in normal and neoplastic neuronal cells.

Immunogen

Extracellular domain of the recombinant mouse receptor expressed in mammalian cells.

Application

Anti-TrkB Antibody is an antibody against TrkB for use in IH.
Immunohistochemistry: 1:3,000. The antibody has been used successfully on rat dorsal root ganglion and trigeminal ganglia in the rat spinal cord (cryostat free-floating sections). Suggested fixative is 4% paraformaldehyde.

Not suitable for Western blot.

Optimal working dilutions must be determined by end user.
Research Category
Neuroscience
Research Sub Category
Neurochemistry & Neurotrophins

Biochem/physiol Actions

Other species have not yet been tested. It is expected to react with a wide range of mammalian species, based on the high sequence similarity.
trkB [BDNF/NT-4/5 growth factor receptor; tyrosine kinase receptor B]. The immunogen sequence was chosen to avoid cross reactivity with trkA or trkC.

Physical form

Lyophilized. Reconstitute with 50 μL of sterile distilled water. Centrifuge to remove any insoluble material. Contains no preservative.
Serum

Preparation Note

Maintain lyophilized material frozen at -20°C to -70°C for up to 12 months after date of receipt. After reconstitution maintain at -20°C in undiluted aliquots for up to 6 months. Avoid repeated freeze/thaw cycles. Glycerol (1:1, ACS or better grade) can be added for additional stability.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


Still not finding the right product?

试用我们的 产品选型工具 工具缩小选择范围


存储类别

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable



分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Matthew D Johnson et al.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 39(2), 1010428317692256-1010428317692256 (2017-02-22)
This study investigated the Trk receptor family as a therapeutic target in pancreatic ductal adenocarcinoma and assessed their prognostic significance. Global gene expression analysis was investigated in prospectively collected pancreatic ductal adenocarcinomas that had either undergone neoadjuvant chemoradiation or were
Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers.
Hernandez, LI; Flenker, KS; Hernandez, FJ; Klingelhutz, AJ; McNamara, JO; Giangrande, PH
Pharmaceuticals (Basel, Switzerland) null
Silvia Ginés et al.
The European journal of neuroscience, 23(3), 649-658 (2006-02-21)
Deficits of neurotrophic support caused by reduced levels of brain-derived neurotrophic factor (BDNF) have been implicated in the selective vulnerability of striatal neurones in Huntington's disease (HD). Therapeutic strategies based on BDNF administration have been proposed to slow or prevent



全球贸易项目编号

货号GTIN
AB987204053252673900